



ITW

Receipt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Liora CAHALON et al

Serial No.: 10/002,145

Filed: December 5, 2001

For: Novel Anti-Cancer Therapeutic Compounds

Examiner:

§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1614

Attorney
Docket: **24214**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the official filing receipt received from the United States Patent and Trademark Office in the above application. Issuance of a corrected filing receipt to correct an error of the USPTO is respectfully requested.

Please add to "Domestic Priority data as claimed by applicant:

"This application claims priority from 09/495,723 02/01/2000 which is a divisional of 08/486,127 06/07/1995, Pat. No. 6,020,323 which is a continuation of 08/436,330 05/10/1995, Pat. No. 5,861,382 which claims priority from PCT/US93/10868 11/09/1993 which is a continuation in part of 08/096,739 07/23/1993, which is a continuation in part of 07/974,750 11/10/1992 which is a continuation in part of 07/878,188 05/01/1992"

A copy of a preliminary amendment, heretofor filed, setting forth the above is attached hereto


Respectfully submitted,

Sol Sheinbein
Registration No. 25,457

Date: August 8, 2004

BEST AVAILABLE COPY

Page 1 of 2




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/002,145	12/05/2001	1614	534	B12/31	13	31	2

CONFIRMATION NO. 4185

UPDATED FILING RECEIPT



OC00000007752796

C/O THE POLKINGHORNS
9003 FLORIN WAY
UPPER MARLBORO, MD 20772

Date Mailed: 03/29/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Liora Cahalon, Givataim, ISRAEL;
Irun R. Cohen, Rehovot, ISRAEL;
Ofer Lider, Kfar Bilu Bet, ISRAEL;
Raanan Margalit, Ganei Yochanan, ISRAEL;

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted 01/10/2002

Projected Publication Date: 06/05/2003

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Novel anti-cancer therapeutic compounds

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



IN THE US PATENT AND TRADEMARK OFFICE

Inventor:

CAHALON et al.

Application Ser. No.: 10/002,145

Filing Date: December 5, 2001

For: NOVEL ANTI-CANCER THERAPEUTIC
COMPOUNDS§
§
§
§
§
§
§
§
§
§Attorney
Docket: B12/31Commissioner of Patents and Trademarks
Washington, D.C. 20231
USAPRELIMINARY AMENDMENT

Sir:

Kindly amend the above-referenced Application as follows, in order to correct
a priority claim:

please delete lines 6-18 on page 1, and substitute the following text:

-- CROSS-REFERENCE TO RELATED APPLICATIONS: This Application claims
priority from US Patent Application No. 09/495,723, filed on February 1, 2000,
currently pending, which is a divisional of US Patent Application No. 08/486,127,
filed on June 7, 1995 and now issued as US Patent No. 6,020,323, on February 1,
2000, which is a continuation of US Patent Application No. 08/436,330, filed on May
10, 1995, now US Patent No. 5,861,382, issued on January 19, 1999, which claims
priority from PCT Application No. PCT/US93/10868, filed on November 9, 1993, and
which is a continuation in part of US Patent Application No. 08/096,739, filed on July


23, 1993, abandoned, which is a continuation in part of US Patent Application No. 07/974,750, filed on November 10, 1992, abandoned, which is a continuation in part of US Patent Application No. 07/878,188, filed on May 1, 1992, abandoned; all of which are owned in common with the present application, and all of which are hereby incorporated by reference as if fully set forth herein. - -

REMARKS

Applicant notes that the above-referenced priority claim was in fact made in the originally filed Application. However, Applicant has now clarified the chain of applications and the relationships between applications thereof. One change has been made: application ser. no. 08/096,739 has now been corrected (it was previously incorrectly noted as ser. no. 07/096,739).

Applicant further notes that the corrected priority claim is being made within four months of the date of filing, on or before April 5, 2002. Applicant respectfully requests that an amended filing receipt be sent, reflecting the priority claim information as stated herein.

Respectfully submitted,



D'vorah Graeser
US Patent Agent
Reg. No. 40,000

Date: March 4, 2002

APPENDIX

CROSS-REFERENCE TO RELATED APPLICATIONS: This Application claims priority from [US Patent No. 6,020,323, filed on June 7, 1995, as US Patent Application No. 08/486,127 and issued on February 1, 2000, which is a continuation of US Patent Application No. 08/436,330, filed on June 29, 1995, now US Patent No. 5,861,382, issued on January 19, 1999, which claims priority from PCT Application No. PCT/US93/10868, filed on November 9, 1993, and which is a continuation in part of US Patent Application No. 07/096,739, filed on July 23, 1993, abandoned, which is a continuation in part of US Patent Application No. 07/974,750, filed on November 10, 1992, abandoned, which is a continuation in part of US Patent Application No. 07/878,188, filed on May 1, 1992, abandoned; and US Patent Application No. 09/495,723, filed on February 1, 2000, currently pending;] US Patent Application No. 09/495,723, filed on February 1, 2000, currently pending, which is a divisional of US Patent Application No. 08/486,127, filed on June 7, 1995 and now issued as US Patent No. 6,020,323, on February 1, 2000, which is a continuation of US Patent Application No. 08/436,330, filed on May 10, 1995, now US Patent No. 5,861,382, issued on January 19, 1999, which claims priority from PCT Application No. PCT/US93/10868, filed on November 9, 1993, and which is a continuation in part of US Patent Application No. 08/096,739, filed on July 23, 1993, abandoned, which is a continuation in part of US Patent Application No. 07/974,750, filed on November 10, 1992, abandoned, which is a continuation in part of US Patent Application No. 07/878,188, filed on May 1, 1992, abandoned [; and

US Patent Application No. 09/495,723, filed on February 1, 2000, currently pending;] all of which are owned in common with the present application, and all of which are hereby incorporated by reference as if fully set forth herein.